Inhaled molgramostim for kids with autoimmune PAP
Part of Lungs & breathing clinical trials.
This study tests an inhaled medicine called molgramostim for children with autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung condition. The goal is to see if the drug can improve lung function and reduce the need for whole lung lavage (a washing procedure).
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 6 and 17 years old.
- Diagnosis of autoimmune pulmonary alveolar proteinosis (aPAP) confirmed by lung biopsy, wash, or CT scan.
- Positive blood test for anti-GM-CSF antibodies (the marker for aPAP).
- Lung function (DLCO) is 70% or below normal for your child's age and hemoglobin level.
- No lung lavage (lung wash) treatment within the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program provides an experimental inhaled medication to people with a rare lung condition called autoimmune pulmonary alveolar proteinosis (aPAP), where the immune system attacks the lungs. The treatment, molgramostim, is given through a nebulizer and may help improve breathing and reduce symptoms.
This trial tests a new way to deliver a protein called GM-CSF directly into the lungs through a tube during a bronchoscopy. It may help people with autoimmune pulmonary alveolar proteinosis (aPAP) breathe better and improve lung function.
This early-phase study tests a treatment that uses gene-corrected immune cells to treat hPAP, a rare lung condition. The goal is to check safety and see whether the treatment improves breathing and lung function.
This study keeps a national record of people with pulmonary alveolar proteinosis (PAP). It includes one “snapshot” group and one group that follows people with autoimmune PAP and asks about symptoms and quality of life.
This Phase 1/2 study tests whether breathing in albuterol can improve symptoms or lung function in people with lymphangioleiomyomatosis (LAM). It’s mainly about safety and early signs of benefit by targeting airflow problems.
This trial tests a device that stimulates the lung to help people whose asthma is not controlled by standard treatments. It may offer a new option for those who still have symptoms despite using inhalers or biologic medicines.
Hear when a new Autoimmune Pulmonary Alveolar Proteinosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.